[{"from": "human", "value": "What can you tell me about this molecule? [C][C][Branch1][C][C][Branch2][Ring2][#Branch2][C][N][C][=Branch1][C][=O][C][C][=N][C][=C][N][=C][C][=Branch2][Ring1][Ring2][=C][Ring1][=Branch1][N][Ring1][=Branch2][C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][#N][C][=C][N][Ring1][S][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable pan-inhibitor of the Janus associated-kinases (JAKs), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, lorpucitinib works in the gastrointestinal (GI) tract where it targets, binds to and inhibits the activity of the JAKs, thereby disrupting JAK-signal transducer and activator of transcription (STAT) signaling pathways and the phosphorylation of STAT proteins. This may inhibit the release of pro-inflammatory cytokines and chemokines, reducing inflammatory responses and preventing inflammation-induced damage. The Janus kinase family of non-receptor tyrosine kinases, which includes tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1), tyrosine-protein kinase JAK2 (Janus kinase 2; JAK2), tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) and non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2), plays a key role in cytokine signaling and inflammaton."}]